원문정보
초록
영어
The rifamycins display a broad spectrum of antibiotic activity against bacteria. Rifamycin B has only very modest activity, but it can be converted chemically into rifamycin SV, which has much more potent activity and was the first rifamycin used clinically. Wild type, A. mediterranei S699, produces only rifamycin B. Therefore, the development of strains which can be used for the direct production of rifamycin SV couldmake the process more economical, by reducing the number of steps required. We investigated a new feeding strategy for high production of rifamycin SV by A. mediterranei MM2 which was developed to produce mostly rifamycin SV. From the
preliminary experiments, it was found that the concentration of rifamycin SV was reached a maximum at 12 days and then sharply decreased after 14 days due to its degradation on the fermentation broth. Therefore, two carbon sources, glucose and glycerol, wereused together or separately, even though glycerol was found to be the best carbon source for rifamycin SV production in our previous study. This strategy significantly increased rifamycin SV yield and DCW, and reduced incubation time up to 2 days.